p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids)

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 39

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

292

HTML

2131

Figures (1-1)

244

Tables (1-4)

237

Sum=2904

Oct 21, 2006 (publication date) through Dec 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Oct 21, 2006; 12(39): 6280-6284
Published online Oct 21, 2006. doi: 10.3748/wjg.v12.i39.6280

Table 1 Gastric endocrine tumor classification, WHO[6]

Classification	Diameter	Ki-67 PI¹	Mitosis	Extension
Well differentiated endocrine tumor (carcinoid tumor)	≤ 1 cm	≤ 2%	≤ 2/10 HPF²	Mucosa- submucosa
Well differentiated endocrine carcinoma (malignant carcinoid)	> 1 cm	> 2%	> 2/10 HPF²	Muscularis propria and beyond
Poorly differentiated endocrine carcinoma (small cell carcinoma)	Any diameter	> 15%	> 10/10 HPF²	Vascular and neural invasion

¹Proliferation index;

²High power field.

Citation: Doganavsargil B, Sarsik B, Kirdok FS, Musoglu A, Tuncyurek M. p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids). World J Gastroenterol 2006; 12(39): 6280-6284
URL: https://www.wjgnet.com/1007-9327/full/v12/i39/6280.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i39.6280